Open AccessHigh Body Mass Index is Associated with Shorter Retention of Tumor Necrosis Factor-Alpha Blocker Treatment in Rheumatoid Arthritis
Author(s) -
Ofir Elalouf,
Merav Lidar,
Tatiana Reitblat,
Devy Zisman,
Alexandra BalbirGurman,
Odelia Hakakian,
Tanya Mashiach,
Ronit Almog,
Ori Elkayam
Publication year - 2021
Publication title -
biologics
Language(s) - English
Resource type - Journals
eISSN - 1177-5491
pISSN - 1177-5475
DOI - 10.2147/btt.s290169
Subject(s) - medicine , golimumab , adalimumab , body mass index , etanercept , hazard ratio , infliximab , overweight , rheumatoid arthritis , gastroenterology , proportional hazards model , surgery , confidence interval , tumor necrosis factor alpha
To evaluate the association between body mass index (BMI) and tumor necrosis factor α (TNF-α) blockers retention in patients with rheumatoid arthritis (RA).